Coverage
-
February 16, 2022
A German court has set aside a €142 million ($161.8 million) damages award issued to Austrian pharmaceutical company AOP Orphan in the midst of a contentious dispute with Taiwanese drug developer PharmaEssentia Corp. over an ill-fated deal to develop a new blood cancer treatment.
1 other articles on this case.
View all »